The problem of @entity712 ( @entity712 ) has become a topic of great interest. Until recently, the use of beta-blockers in @entity1 with @entity712 was considered as a contraindication. Times have changed and the contraindicated drug is now an advised and preferred one to be used in @entity712 @entity1 with certain advised recommendations for its use in a safe and beneficial way. Still we need to emphasize the benefits of these agents in order to achieve more application in @entity712 @entity1 . Here we try to stress the proved beneficial effects of beta-blockers by major studies in @entity712 @entity1 , and to supply the reader with practical information regarding the use of these agents with a look at the frequency of using them and the possible reasons behind their underuse. The files of @entity712 @entity1 admitted to 1st Internal Department in the University Hospital in Bratislava in the period between January and December 1997 were checked to show the magnitude of using beta-blockers in them. Among 150 @entity1 admitted during the above mentioned period only 30 @entity1 (20%) received beta-blockers. It seems that beta-blockers have to be used in all @entity1 with @entity712 with reduced ejection fraction unless a real contraindication exists, but the actual data shows that beta-blockers are still underused. (Tab. 2, Ref. 30.)

Benefits of beta-blockers in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'heart failure']
@entity712 :: (MESH:D006333,Disease) :: ['heart failure']
